<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="pmc-domain-id">2593</journal-id><journal-id journal-id-type="pmc-domain">frontcdb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11524909</article-id><article-id pub-id-type="pmcid-ver">PMC11524909.1</article-id><article-id pub-id-type="pmcaid">11524909</article-id><article-id pub-id-type="pmcaiid">11524909</article-id><article-id pub-id-type="pmid">39483334</article-id><article-id pub-id-type="doi">10.3389/fcell.2024.1478478</article-id><article-id pub-id-type="publisher-id">1478478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Glioma-associated oncogene homolog 1 in breast invasive carcinoma: a comprehensive bioinformatic analysis and experimental validation</article-title><alt-title alt-title-type="left-running-head">Qi et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fcell.2024.1478478" ext-link-type="uri">10.3389/fcell.2024.1478478</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Qi</surname><given-names initials="T">Teng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2763491/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Y">Yujie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2867085/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wan</surname><given-names initials="J">Junhao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2866986/overview"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="B">Bo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2815123/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="J">Jinsuo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2866851/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="J">Jie</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1827790/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="Y">Ye</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wu</surname><given-names initials="H">He</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1674577/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lv</surname><given-names initials="Y">Yonggang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1772238/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ji</surname><given-names initials="F">Fuqing</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2676376/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>School of Medicine</institution>, <institution>Northwest University</institution>, <addr-line>Xi&#8217;an</addr-line>, <addr-line>Shaanxi</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Xi&#8217;an NO.3 Hospital</institution>, <institution>The Affiliated Hospital of Northwest University</institution>, <addr-line>Xi&#8217;an</addr-line>, <addr-line>Shaanxi</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/670750/overview" ext-link-type="uri">Xiaosheng Tan</ext-link>, Rutgers, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2767102/overview" ext-link-type="uri">Yang Li</ext-link>, Albert Einstein College of Medicine, United States</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1936144/overview" ext-link-type="uri">Yancui Sun</ext-link>, Dalian Medical University, China</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2724049/overview" ext-link-type="uri">Laixing Zhang</ext-link>, University of California, Los Angeles, United States</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2765053/overview" ext-link-type="uri">Meng Jia</ext-link>, University of Pennsylvania, United States</p></fn><corresp id="c001">*Correspondence: He Wu, <email>hewu6768@gmail.com</email>; Yonggang Lv, <email>lvygwytt@163.com</email>; Fuqing Ji, <email>jifuqing1984@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">454532</issue-id><elocation-id>1478478</elocation-id><history><date date-type="received"><day>09</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>04</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>31</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-01 09:25:15.990"><day>01</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Qi, Hu, Wan, Zhao, Xiao, Liu, Cheng, Wu, Lv and Ji.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Qi, Hu, Wan, Zhao, Xiao, Liu, Cheng, Wu, Lv and Ji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcell-12-1478478.pdf"/><abstract><sec><title>Background</title><p>Breast cancer, despite significant advancements in treatment, remains a major cause of cancer-related deaths among women. Immunotherapy, an emerging therapeutic strategy, offers promise for better outcomes, particularly through the modulation of immune functions. Glioma-Associated Oncogene Homolog 1 (GLI1), a transcription factor implicated in cancer biology, has shown varying roles in different cancers. However, its immunoregulatory functions in breast invasive carcinoma (BRCA) remain elusive. The current study aimed to unravel the expression patterns and immune-regulatory roles of GLI1 in BRCA.</p></sec><sec><title>Methods</title><p>Utilizing multiple bioinformatic platforms (TIMER2.0, GEPIA2, and R packages) based on The Cancer Genome Atlas (TCGA) and/or Genotype-Tissue Expression (GTEx) databases, we analyzed the expression of GLI1 in BRCA and its pan-cancer expression profiles. We further validated these findings by conducting qPCR and immunohistochemical staining on clinical BRCA samples. Kaplan-Meier analysis and Cox proportional hazards regression were performed to assess the prognostic value of GLI1. Additionally, the association between GLI1 expression and immune infiltration within the tumor immune microenvironment (TMIE) was examined.</p></sec><sec><title>Results</title><p>The findings reveal dysregulated expression of GLI1 in numerous cancers, with a significant decrease observed in BRCA. High GLI1 expression indicated better survival outcomes and was correlated with the age and stage of BRCA patients. GLI1 was involved in immune status, as evidenced by its strong correlations with immune and stromal scores and the infiltration levels of multiple immune cells. Meanwhile, GLI1 was co-expressed with multiple immune-related genes, and high GLI1 expression was associated with the activation of immune-related pathways, such as binding to proteasome and mismatch repair and retinol metabolism signaling pathways. Additionally, the differential expression of GLI1 may be related to the effect of immunotherapy on CTLA-4, PD-1, and other signals, and can effectively predict the immune efficacy.</p></sec><sec><title>Conclusion</title><p>Our study underscores the critical role of GLI1 in BRCA, both as a potential tumor suppressor and an immune regulator. The association between GLI1 expression and favorable prognosis suggests its potential as a prognostic biomarker and immunotherapeutic target in BRCA.</p></sec></abstract><kwd-group><kwd>glioma-associated oncogene homolog 1</kwd><kwd>breast invasive carcinoma</kwd><kwd>immune infiltration</kwd><kwd>prognostic</kwd><kwd>tumor immune microenvironment</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Shaanxi Provincial Health Research Fund Project (No. 2022B003), the Shaanxi Provincial general project for social development (No. 2024SF-YBXM-220) and Xi&#8217;an No.3 Hospital (No. Y2023yxy j01). Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Xi&#8217;an NO.3 hospital.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cellular Biochemistry</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Breast cancer presents high heterogeneity in histology, genetics, and prognosis (<xref rid="B29" ref-type="bibr">Prat and Perou, 2011</xref>) ranking as the second leading cause of cancer-related deaths in women, following lung cancer (<xref rid="B8" ref-type="bibr">DeSantis et al., 2011</xref>). It is commonly categorized into three major subtypes based on the expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2/ERBB2): luminal type (hormone receptor positive/ERBB2 negative, accounting for 70% of patients), ERBB2 positive (15%&#8211;20%), and triple-negative (TNBC, representing 15% of cases) (<xref rid="B34" ref-type="bibr">S&#248;rlie et al., 2001</xref>; <xref rid="B14" ref-type="bibr">Hui and Angers, 2011</xref>). The primary treatment modalities for breast cancer include surgery, conventional chemotherapy, and radiotherapy (often involving targeted drugs), but many patients encounter resistance, relapse, and secondary metastasis (<xref rid="B24" ref-type="bibr">Loibl et al., 2021</xref>). Despite advancements in multimodal therapy, early-stage breast cancer is considered curable in 70%&#8211;80% of cases, while managing advanced metastatic breast cancer remains a formidable challenge (<xref rid="B31" ref-type="bibr">Riggio et al., 2021</xref>). Immunotherapy has emerged as a promising approach in cancer treatment, showing efficacy across various cancer types (<xref rid="B49" ref-type="bibr">Zhang and Zhang, 2020</xref>; <xref rid="B5" ref-type="bibr">Chow et al., 2022</xref>). Although some immunotherapies, such as pembrolizumab (<xref rid="B27" ref-type="bibr">Nanda et al., 2020</xref>), and opdivo combined with ipilimumab, have demonstrated prolonged survival in breast cancer, a comprehensive understanding of immune infiltrates within the tumor immune microenvironment (TMIE) of BRCA is crucial for the development of more precise immunotherapeutic strategies (<xref rid="B1" ref-type="bibr">Adams et al., 2022</xref>).</p><p>Glioma-Associated Oncogene Homolog 1 (GLI1) was first identified as an amplified gene in human malignant glioma (<xref rid="B18" ref-type="bibr">Kinzler et al., 1987</xref>), and subsequently recognized as a member of the Kruppel family of zinc finger-containing transcription factors (<xref rid="B19" ref-type="bibr">Kinzler et al., 1988</xref>; <xref rid="B20" ref-type="bibr">Kinzler and Vogelstein, 1990</xref>). GLI1 is recognized as the nuclear mediator of the Shh signaling pathway, which governs diverse aspects of early central nervous system development (<xref rid="B6" ref-type="bibr">Dahmane et al., 2001</xref>), including potential involvement in floor cell and ventral neuron differentiation in the neural tube, proliferation of granule cell precursors in the cerebellum, and growth of the dorsal brain (<xref rid="B9" ref-type="bibr">Echelard et al., 1993</xref>; <xref rid="B32" ref-type="bibr">Roelink et al., 1994</xref>; <xref rid="B6" ref-type="bibr">Dahmane et al., 2001</xref>). In previous studies, it has been widely postulated that the GLI1 protein family potentially exerts a significant impact on tumor progression and metastasis (<xref rid="B50" ref-type="bibr">Zhu and Lo, 2010</xref>). In addition, accumulating evidence has shown that GLI1 plays a crucial role in regulating numerous cellular processes relevant to cancer, including cancer stemness, epithelial-mesenchymal transition, proliferation, cell cycle regulation, cell survival, programmed cell death, and reduced cell viability (<xref rid="B35" ref-type="bibr">Sun et al., 2014</xref>; <xref rid="B42" ref-type="bibr">Xu et al., 2014</xref>). Consequently, GLI1 contributes to the progression of multiple cancer types, including colorectal cancer, liver cancer, stomach cancer, pancreatic cancer, lung cancer, gallbladder cancer, prostate cancer, ovarian cancer, and glioblastoma (<xref rid="B2" ref-type="bibr">Akiyoshi et al., 2006</xref>; <xref rid="B28" ref-type="bibr">Olive et al., 2009</xref>; <xref rid="B17" ref-type="bibr">Kandala and Srivastava, 2012</xref>; <xref rid="B10" ref-type="bibr">Fernandez-Zapico, 2013</xref>; <xref rid="B11" ref-type="bibr">Gao et al., 2013</xref>; <xref rid="B23" ref-type="bibr">Li et al., 2016</xref>; <xref rid="B12" ref-type="bibr">Gu et al., 2021</xref>; <xref rid="B15" ref-type="bibr">Ichimiya et al., 2021</xref>; <xref rid="B30" ref-type="bibr">Quan et al., 2022</xref>; <xref rid="B40" ref-type="bibr">Wu et al., 2022</xref>). In addition, GLI1 appears to regulate tumor progression and metastasis by mediating components of TMIE. For example, GLI1 is co-ectopically removed with pSTAT3 by chondroitin-6-sulfate (C-6-S) to activate the JAK/STAT3 and Hedgehog pathways to induce immune rejection (<xref rid="B40" ref-type="bibr">Wu et al., 2022</xref>), through the activity of the aPKC-&#953;/GLI1 pathway (<xref rid="B38" ref-type="bibr">Tian et al., 2018</xref>). Promote GLI1 nuclear localization and binding to target gene promoter, promote gallbladder cancer metastasis and macrophage recruitment. These properties make GLI1 a promising target for cancer treatment. Nevertheless, the immunoinfiltration and tumor microenvironment of GLI1 in breast cancer have been poorly studied.</p><p>With the aim of comprehensively investigating the significance of GLI1 in breast invasive carcinoma (BRCA), this study was designed to address three key aspects. Firstly, it examined the expression of GLI1 in BRCA and its association with clinicopathological features and prognosis. Secondly, it explored the correlation between GLI1 expression and immune cell infiltration, as well as the levels of immune checkpoints within the TMIE, while analyzing the potential links between GLI1 expression and CTLA-4 and PD-1 immunotherapy. Lastly, it delved into the functional pathways related to GLI1 expression, aiming to uncover the underlying molecular mechanisms. The findings of this study will serve to provide valuable evidence regarding the role of GLI1 in breast cancer and its potential as both a prognostic biomarker and a therapeutic target.</p></sec><sec sec-type="materials|methods" id="s2"><title>2 Materials and methods</title><sec id="s2-1"><title>2.1 Data sources and differential analysis of GLI1 expression</title><p>Expression of GLI1 between tumor tissues and the corresponding normal tissues in pan-cancer were analyzed using the &#8220;Gene_DE Module&#8221; of TIMER2.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://timer.cistrome.org/2022" ext-link-type="uri">http://timer.cistrome.org/2022</ext-link> accessed on 11 November 2023) (<xref rid="B22" ref-type="bibr">Li et al., 2020</xref>) and GEPIA (version 2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://gepia.cancer-pku.cn/2022" ext-link-type="uri">http://gepia.cancer-pku.cn/2022</ext-link> accessed on 11 November 2023) (<xref rid="B36" ref-type="bibr">Tang et al., 2017</xref>). In addition, the transcriptome data of 33 pan-cancer types in the TCGA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tcga.xenahubs.net" ext-link-type="uri">https://tcga.xenahubs.net</ext-link> accessed on 11 November 2023, The abbreviations corresponding to the 33 cancer types and the analyzed sample sizes can be found in <xref rid="s12" ref-type="sec">Supplementary Table 1</xref>) (<xref rid="B4" ref-type="bibr">Blum et al., 2018</xref>) were downloaded, and the differential expression of GLI1 was analyzed with the aid of the Wilcoxon test provided in the R package. Through these three ways, data were divided into high and low expression groups based on the median expression value of GLI1 expression. False discovery rate &lt;0.05 indicated statistical significance.</p><p>Data from the TCGA online database, where the Transcripts Per Million (TPM) data did not contain zero values, allowing for the direct application of log2 (TPM). In contrast, incorporation data from the GTEx project, where the potential presence of zero values in the TPM data necessitated the use of log2 (TPM+1) to avoid mathematical errors in logarithmic calculations and ensure the validity of our statistical analysis.</p><p>Based on our analysis and the preliminary research directions of our department, we have decided to focus on a more in-depth investigation of GLI1 in invasive breast cancer. Gene expression profiles of BRCA and normal samples from the TCGA and GTEx (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://commonfund.nih.gov/GTEx/)(2013" ext-link-type="uri">http://commonfund.nih.gov/GTEx/)</ext-link> (<xref rid="B25" ref-type="bibr">Lonsdale et al, 2013</xref>) databases were obtained for differential analysis of GLI1 expression between tumor and normal tissues using the Wilcoxon test. Statistical significance was determined at FDR &lt;0.05. To mitigate potential batch effects arising from the use of different sequencing platforms and protocols, we analyzed the gene expression data from TCGA and GTEx databases separately using TIMER2.0 and GEPIA, both of which apply normalization procedures tailored to the respective data sources during preprocessing. TIMER2.0 integrates RNA sequencing data from various public databases, including TCGA and GTEx, and applies standardization methods such as Reads Per Kilobase Million (RPKM) or TPM to ensure comparability across samples. It also corrects for batch effects using algorithms like ComBat and addresses missing values through imputation techniques. Similarly, GEPIA2 utilizes TCGA and GTEx data, employing TPM standardization and conducting differential expression analyses with statistical methods such as t-tests and survival analyses. The expression distribution of GLI1 was visualized using the &#8220;ggpubr&#8221; R package, represented in the form of a boxplot.</p></sec><sec id="s2-2"><title>2.2 Quantitative real-time PCR</title><p>Tissue samples were obtained from 5 patients diagnosed with breast invasive carcinoma, comprising both tumor and adjacent non-cancerous tissues. The samples were collected by the Breast Surgery Department of Xi&#8217;an NO.3 Hospital. The study protocol was approved by the Ethics Committee of Xi&#8217;an No. 3 Hospital, and informed consent was obtained from all patients for the collection of samples. All patients provided informed consent, and detailed diagnostic information is provided in <xref rid="s12" ref-type="sec">Supplementary Table 2</xref>. The primers used in the experiments are listed in <xref rid="T1" ref-type="table">Table 1</xref>. Total RNA was extracted from these samples. Subsequently, cDNA was synthesized from the extracted RNA. Quantitative Real-Time PCR (qPCR) was then employed to assess GLI1 expression levels, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as the internal reference gene for normalization. This approach ensures robust validation of GLI1 expression patterns in the context of breast invasive carcinoma. To analyze the differential expression of GLI1 in breast invasive carcinoma between cancer and normal groups, we conducted a two-sample <italic toggle="yes">t</italic>-test using the qPCR data. This statistical method compares the means of two groups to determine whether they are significantly different. In our analysis, we utilized the R language to perform the <italic toggle="yes">t</italic>-test, which provided us with a t-statistic, <italic toggle="yes">p</italic>-value, confidence interval for the difference in means, and sample estimates of the mean GLI1 expression levels for both groups.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>The primers used in the experiments.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Primer name</th><th align="center" rowspan="1" colspan="1">Primer sequence 5&#8242;-3&#8242;</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Human-actin-F</td><td align="center" rowspan="1" colspan="1">CAG&#8203;ATG&#8203;TGG&#8203;ATC&#8203;AGC&#8203;AAG&#8203;CAG&#8203;GAG</td></tr><tr><td align="center" rowspan="1" colspan="1">Human-actin-R</td><td align="center" rowspan="1" colspan="1">GTC&#8203;AAG&#8203;AAA&#8203;GGG&#8203;TGT&#8203;AAC&#8203;GCA&#8203;ACT&#8203;AAG</td></tr><tr><td align="center" rowspan="1" colspan="1">Human-GLI1-F2</td><td align="center" rowspan="1" colspan="1">GCG&#8203;TGA&#8203;GCC&#8203;TGA&#8203;ATC&#8203;TGT&#8203;GTA&#8203;TG</td></tr><tr><td align="center" rowspan="1" colspan="1">Human-GLI1-R2</td><td align="center" rowspan="1" colspan="1">CGT&#8203;GGA&#8203;TGT&#8203;GCT&#8203;CGC&#8203;TGT&#8203;TG</td></tr></tbody></table></table-wrap></sec><sec id="s2-3"><title>2.3 Immunohistochemical staining</title><p>5 tumor specimens and 5 adjacent non-cancerous specimens were sectioned into 3.5&#160;&#181;m thick paraffin slices. Following dewaxing, rehydration, and antigen retrieval, the sections were incubated overnight at 4&#176;C with anti-GLI1 antibody (SC-166907, 1:500, Santa Cruz, CA, United States). All slides were covered with poly-HRR goat antibody, followed by incubation with diaminobenzidine solution (3&#8211;5&#160;min) and counterstaining with hematoxylin. Finally, the sections were observed under a fluorescence microscope.</p></sec><sec id="s2-4"><title>2.4 GLI1 expression is associated with the prognosis of patients with BRCA</title><p>The clinicopathological and survival data of BRCA samples were obtained from the TCGA database. To assess the prognostic value of GLI1 in BRCA, all BRCA samples were categorized into high and low GLI1 expression groups based on their median expression values. Survival analysis, including overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI), and disease-free interval (DFI), was performed using the R survival package, and the results were visualized as Kaplan-Meier curves with log-rank <italic toggle="yes">p</italic>-values. Additionally, the &#8220;limma&#8221; R package was used to conduct differential analysis of clinical information (including age, gender, tumor pathological stage, and tumor TNM stage) downloaded from the TCGA database, aiming to evaluate the association between GLI1 and clinical factors. The results were visualized through boxplots and heatmaps using the &#8220;ggpubr&#8221; and &#8220;ComplexHeatmap&#8221; R packages, respectively.</p></sec><sec id="s2-5"><title>2.5 Immune infiltration in BRCA</title><p>The correlation between GLI1 and immune cell infiltration was assessed using the &#8220;Gene Module&#8221; of TIMER2.0 (<xref rid="B22" ref-type="bibr">Li et al., 2020</xref>). This module generated scatter plots displaying Spearman&#8217;s correlations between GLI1 expression and tumor purity, as well as the abundance of six immune cell types, including DCs, B cells, neutrophils, CD4<sup>+</sup> T cells, macrophages, and CD8<sup>+</sup> T cells. Additionally, stromal and immune scores were calculated using the R &#8220;ESTIMATE&#8221; package, with the sum of these scores representing the ESTIMATE score, which indirectly reflects tumor purity (<xref rid="B46" ref-type="bibr">Yoshihara et al., 2013</xref>). The infiltrating abundance of immune cells in BRCA tissues was estimated using the CIBERSORT algorithm, a computational method that quantifies fractions of 22 cell types from bulk tissue gene expression profiles. The xCELL algorithm was also employed to assess the immune cell infiltration in BRCA samples from TCGA database. xCELL is a computational method that estimates the abundance of various immune and stromal cell types in tumor tissues based on bulk gene expression profiles. Specifically, we utilized the Pearson correlation coefficient (Pearson R) to evaluate the correlation between the expression of GLI1, a key gene of interest, and the inferred abundances of various immune cell types. The Pearson correlation coefficient provides a measure of the linear dependence between two variables, allowing us to identify potential associations between GLI1 expression and immune cell infiltration patterns. The correlations between GLI1 expression, stromal and immune scores, and immune cell infiltration abundance were further analyzed using R packages such as &#8220;ggplot2,&#8221; &#8220;ggpubr&#8221; and &#8220;ggExtra.&#8221;</p></sec><sec id="s2-6"><title>2.6 Co-expression analysis and immune checkpoint analysis in BRCA</title><p>Chemokine and other Immune genes are crucial in determining the composition of the tumor immune microenvironment. Co-expression analysis between GLI1 expression and the expression of immunosuppressive and immune activation genes, as well as MHC, chemokine, and chemokine receptor-related genes, was performed using the R &#8220;limma&#8221; package. Expression data of immune checkpoint genes were extracted, and their expression in two groups of BRCA samples stratified by high and low GLI1 expression was analyzed using the R &#8220;ggplot2&#8221; package. Furthermore, four groups of immune therapy scores of BRCA samples were downloaded from the TCIA database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tcia.at/" ext-link-type="uri">https://tcia.at/</ext-link> accessed on 11 November 2023). Differential analysis between the GLI1 expression groups and immune therapy scores was conducted using the R &#8220;limma&#8221; package, and the results were visualized through violin plots created with the R package &#8220;ggpubr.&#8221;</p></sec><sec id="s2-7"><title>2.7 Gene set enrichment analysis (GSEA)</title><p>With the predefined GO and KEGG gene sets in GSEA website as an enrichment reference, GSEA was conducted to analyze the GO annotations terms and KEGG pathways that were significantly associated with GLI1 expression using the online visualization tool &#8220;sangerbox3.0&#8221;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.sangerbox.com/" ext-link-type="uri">http://www.sangerbox.com/</ext-link> accessed on 11 November 2023).</p></sec><sec id="s2-8"><title>2.8 Drug sensitivity analysis</title><p>We employed the Comprehensive Pancancer Analysis of Drug Sensitivity (CPADS) web platform (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://smuonco.shinyapps.io/CADSP/" ext-link-type="uri">https://smuonco.shinyapps.io/CADSP/</ext-link>) to investigate the drug sensitivity profiles associated with the GLI1 gene in breast cancer (BRCA). The CPADS platform integrates data from multiple sources, including the Gene Expression Omnibus (GEO), TCGA, and Genomics of Drug Sensitivity in Cancer (GDSC) databases, allowing for comprehensive analysis of differential gene expression and drug response.</p><p>Specifically, we focused on the GLI1 gene to assess its influence on drug sensitivity in BRCA. Utilizing the GDSC and TCGA module within CPADS, we analyzed the IC50 values (half-maximal inhibitory concentration) of various anticancer drugs in BRCA samples with high and low expression levels of GLI1. The IC50 values represent the drug concentration required to inhibit 50% of cellular growth and are commonly used as a metric for drug sensitivity.</p></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><sec id="s3-1"><title>3.1 Expression pattern of GLI1 in pan-cancer</title><p>In order to evaluate the potential of GLI1 as a therapeutic target, we initially examined the expression pattern of GLI1 across various types of cancers, comparing tumor tissues with their corresponding normal tissues. Our analysis using TIMER2.0 revealed a significant reduction in GLI1 expression in tumor tissues compared to their matched normal controls in several cancer types, including BLCA, BRCA, KIRP, THCA, and UCEC. Conversely, GLI1 exhibited higher expression levels in CHOL, HNSC, KIRC, LIHC, and STAD compared to their matched controls (<xref rid="F1" ref-type="fig">Figure 1A</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Expressions of GLI1 in pan-cancers. Expression levels of GLI1 in various cancers or tumor tissues and adjacent non-tumor tissues analyzed by TIMER2.0 <bold>(A)</bold>, GEPIA2 <bold>(B)</bold> and the R package <bold>(C)</bold> based on TCGA and/or GTEx databases. *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.01, ***<italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g001.jpg"/></fig><p>GEPIA, utilizing tumor tissues from TCGA and normal tissues from GTEx project, revealed the tumor-specific expression patterns of GLI1 (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Additionally, the R package was utilized to further analyze the expression levels of GLI1 across 33 cancer types in the TCGA database. The results were largely consistent with those obtained from TIMER2.0 (<xref rid="F1" ref-type="fig">Figure 1C</xref>). GLI1 expression was found to be elevated in CHOL, HNSC, KIRC, LIHC, and STAD, while it was decreased in BLCA, BRCA, CESC, KIRP, THCA, THYM, and UCEC.</p></sec><sec id="s3-2"><title>3.2 Expression pattern of GLI1 in breast invasive carcinoma</title><p>We conducted a comprehensive investigation into the expression distribution of GLI1 in BRCA. Analysis of sample data from TCGA and GTEx revealed a significant decrease in GLI1 expression in tumor samples compared to normal tissue samples (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Due to a high CT value and unexpected melting curve of actin amplification in a tumor sample, it was deemed unsuitable for qPCR experiments. Ultimately, we proceeded with qPCR on 4 tumor samples and 5 adjacent non-cancerous samples. Experimental results are presented in <xref rid="F2" ref-type="fig">Figure 2B</xref>, indicating significantly higher expression in adjacent non-cancerous tissues compared to tumor tissues (<italic toggle="yes">p</italic> = 2.842e-06). Immunohistochemistry results, displayed in <xref rid="F2" ref-type="fig">Figures 2C, D</xref>; <xref rid="s12" ref-type="sec">Supplementary Figure 1</xref>, clearly show deeper staining intensity for GLI1 in adjacent non-cancerous tissues than in tumor tissues. GLI1 gene staining in breast cancer tissues appears lighter compared to adjacent tissues, suggesting lower GLI1 expression levels in breast cancer tissues, thus confirming the hypothesis from previous experimental data that gli1 gene functions as a tumor suppressor gene. This experiment was approved by the Ethics Committee of Xi&#8217;an NO.3 hospital. These findings collectively indicate a significant reduction in both mRNA and protein levels of GLI1 in BRCA tissue samples.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Expression pattern of GLI1 in BRCA. <bold>(A)</bold>, Differential expression of GLI1 between BRCA tissue and normal tissue samples in TCGA and GTEx; <bold>(B)</bold>, The qPCR results; <bold>(C, D)</bold>, Representative images and quantification of immunohistochemical staining for GLI1 in BRCA tissue and normal tissue for patient 1 and 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g002.jpg"/></fig></sec><sec id="s3-3"><title>3.3 GLI1 expression is associated with prognosis of patients with BRCA</title><p>After adjusting for variables such as age, the prognostic significance of GLI1 in BRCA was assessed through survival analyses evaluating four key outcomes. Our findings revealed that BRCA patients with low GLI1 expression exhibited notably poorer overall survival (OS, <italic toggle="yes">p</italic> = 0.009), disease-specific survival (DSS, <italic toggle="yes">p</italic> = 0.017), and progression-free interval (PFI, <italic toggle="yes">p</italic> = 0.040) compared to those with high GLI1 expression (<xref rid="F3" ref-type="fig">Figures 3A&#8211;C</xref>), highlighting the correlation between GLI1 expression and the survival outcomes of BRCA patients. However, no significant associations were found between GLI1 expression and the disease-free interval (DFI, <italic toggle="yes">p</italic> = 0.067) in BRCA patients (<xref rid="F3" ref-type="fig">Figure 3D</xref>). It is important to highlight that the Kaplan-Meier plotter, based on disease-specific survival and progression-free interval, exhibits a crossing point around the 8th year. Notably, the survival outcome of the high-low expression group deviates from the aforementioned trend after the 8th year. This suggests that the effect of GLI1 expression on survival outcomes may be time-dependent, with GLI1 expression levels having a more pronounced influence in the earlier years post-diagnosis. These findings suggest a potential collaboration between GLI1 and other factors in influencing patient prognosis.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Prognostic value of GLI1 in BRCA. <bold>(A&#8211;D)</bold>, Survival curves showing the differences on overall survival <bold>(A)</bold>, disease-specific survival <bold>(B)</bold>, progression-free interval <bold>(C)</bold> and disease-free interval <bold>(D)</bold> between high and low GLI1 expression; <bold>(E&#8211;J)</bold>, Correlation box diagram of GLI1 expression difference and clinical factors; <bold>(K)</bold>, Heat map of correlation between GLI1 expression difference and clinical factors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g003.jpg"/></fig><p>The correlation between the expression of GLI1 and various clinical factors, including age, sex, histopathological stage, and TNM stage (<xref rid="F3" ref-type="fig">Figures 3E&#8211;J</xref>), was further investigated. Our analysis revealed that the expression of GLI1 was correlated with age, specific histopathological stages, and T stages (<xref rid="F3" ref-type="fig">Figure 3K</xref>). Specifically, the expression of GLI1 was found to be significantly higher in patients aged &#8804;65 compared to those aged &gt;65 (P = 2e-5). Furthermore, statistically significant differences in GLI1 expression were observed between stage I and stage II (<italic toggle="yes">p</italic> = 0.00016), stage I and stage IV (<italic toggle="yes">p</italic> = 0.024), as well as stage II and stage III (<italic toggle="yes">p</italic> = 0.0084) within the histopathologic staging. Similarly, significant variations in GLI1 expression were noted between T1 and T2 (<italic toggle="yes">p</italic> = 1.4e-05), T1 and T4 (<italic toggle="yes">p</italic> = 0.0015), T2 and T3 (<italic toggle="yes">p</italic> = 0.00046), as well as T3 and T4 (<italic toggle="yes">p</italic> = 0.0023) within the T stage of the tumor. However, no significant difference in GLI1 expression was observed between M0 (no distant metastasis) and M1 (presence of distant metastasis) stages in breast cancer (<italic toggle="yes">p</italic> = 0.06).</p></sec><sec id="s3-4"><title>3.4 Association of GLI1 expression with immune infiltrates in BRCA</title><p>The involvement of GLI1 in the immune infiltrates within the TMIE of BRCA was further examined using various methods. The correlations between GLI1 expression and the infiltration levels of six main types of immune cells were explored using TIMER2.0. Patients with BRCA who exhibited low infiltration abundance of only B cells appeared to have a worse cumulative survival rate compared to those with high infiltration abundance (<italic toggle="yes">p</italic> = 0.046, <xref rid="F4" ref-type="fig">Figure 4A</xref>). Notably, GLI1 expression exhibited significant positive correlations with the following immune cell types: DCs (r = 0.136, <italic toggle="yes">p</italic> = 2.75e-05), neutrophils (r = 0.099, <italic toggle="yes">p</italic> = 2.26e-03), CD4<sup>+</sup> T cells (r = 0.259, <italic toggle="yes">p</italic> = 3.64e-16), CD8<sup>+</sup> T cells (r = 0.225, <italic toggle="yes">p</italic> = 1.23e-12), and macrophages (r = 0.101, <italic toggle="yes">p</italic> = 1.60e-03). Conversely, GLI1 expression displayed a negative correlation with B cells (r = 0.183, <italic toggle="yes">p</italic> = 5.56e&#8722;5) and tumor purity (r = &#8722;0.406, <italic toggle="yes">p</italic> = 7.76e-14) in BRCA (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Furthermore, a significant positive correlation was observed between GLI1 expression and both stromal (r = 0.47, <italic toggle="yes">p</italic> &lt; 2.2e&#8722;16) and immune (r = 0.42, <italic toggle="yes">p</italic> &lt; 2.2e&#8722;16) scores in BRCA (<xref rid="F4" ref-type="fig">Figures 4C, D</xref>). Additionally, using CIBERSORT, correlation analysis was performed to assess the relationship between GLI1 expression and the infiltration abundance of 11 immune cell types (<xref rid="F4" ref-type="fig">Figures 4E&#8211;O</xref>). The results indicated that GLI1 expression positively correlated with naive B cells (r = 0.42, <italic toggle="yes">p</italic> &lt; 2.2e-16), resting dendritic cells (r = 0.22, <italic toggle="yes">p</italic> = 3.3e-13), resting mast cells (r = 0.19, <italic toggle="yes">p</italic> = 1.5e-10), plasma cells (r = 0.17, <italic toggle="yes">p</italic> = 3.2e-08), resting memory CD4<sup>+</sup>T cells (r = 0.13, <italic toggle="yes">p</italic> = 1.6e-05), CD8<sup>+</sup>T cells (r = 0.22, <italic toggle="yes">p</italic> = 1.3e-13), and &#947;&#948;T cells (r = 0.14, <italic toggle="yes">p</italic> = 7.4e-06). Conversely, GLI1 expression exhibited negative correlations with activated dendritic cells (r = &#8722;0.12, <italic toggle="yes">p</italic> = 7.6e-05),macrophages M0 (r = &#8722;0.32, <italic toggle="yes">p</italic> &lt; 2.2e&#8722;16), macrophages M2 (r = &#8722;0.3, <italic toggle="yes">p</italic> &lt; 2.2e&#8722;16), and neutrophils (r = &#8722;0.28, <italic toggle="yes">p</italic> &lt; 2.2e&#8722;16) in BRCA. Finally, the xCELL tool was employed to validate the infiltration of immune cells by GLI1, yielding results that were largely consistent (<xref rid="F4" ref-type="fig">Figure 4P</xref>), thereby validating the robustness of the previously mentioned results.</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Associations of GLI1 with immune infiltration in BRCA. <bold>(A)</bold>, Cumulative survival of BRCA patients with high and low infiltrating levels of six immune cells in TIMER2.0; <bold>(B)</bold>, Correlations between GLI1 expression and infiltrating levels of six immune cells in TIMER2.0; <bold>(C, D)</bold>, Correlations of GLI1 expression with stromal <bold>(C)</bold> and immune <bold>(D)</bold> scores; <bold>(E&#8211;O)</bold>, Correlations between GLI1 expression and infiltrating levels of the immune cells by CIBERSORT; <bold>(P)</bold> Correlations between GLI1 expression and infiltrating levels of the immune cells by xCELL.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g004.jpg"/></fig></sec><sec id="s3-5"><title>3.5 Associations of GLI1 expression with immune status related genes and immunotherapy</title><p>The expression of the GLI1 gene exhibited a strong positive correlation with the majority of chemokine genes, as illustrated in <xref rid="F5" ref-type="fig">Figure 5A</xref> (e.g., CCL14, CXCL12, and CCL16). Conversely, the correlation analysis of receptor genes depicted minimal statistical significance, as demonstrated in <xref rid="F5" ref-type="fig">Figure 5B</xref>. Upon examining the correlation with MHC genes, depicted in <xref rid="F5" ref-type="fig">Figure 5C</xref>, we observed a significant positive correlation with certain genes (e.g., CCR9, etc.), and a notable negative correlation with another set of genes (e.g., HLA-A/B/C, HLA-DRB1, etc.). Analysis of the correlation between genes encoding immunoinhibitors and immunostimulators (<xref rid="F5" ref-type="fig">Figures 5D, E</xref>) revealed that the majority of statistically significant molecules were positively correlated with GLI1, including CD160, KDR, CD80, CD28, KLRK1, and HHLAF. Furthermore, examination of immune checkpoint genes (<xref rid="F5" ref-type="fig">Figures 5F, G</xref>) demonstrated a positive correlation between GLI1 and certain immune checkpoint suppressor genes, such as IL4, as well as with over half of the immune checkpoint promoting genes, including CD80, IL1A, CD40LG, TLR4, and IFNA1,2.</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Associations of GLI1 expression with immune status-related genes and immunotherapy. Co-expression of GLI1 expression with chemokines <bold>(A)</bold>, receptors <bold>(B)</bold>, MHC <bold>(C)</bold>, immunoinhibitors <bold>(D)</bold>, immunostimulators <bold>(E)</bold>, immune checkpoint suppressor genes <bold>(F)</bold> and immune checkpoint-promoting genes <bold>(G)</bold>. Correlation analysis of gene expression and combined application of immunotherapy CTLA-4 and PD-1 <bold>(H&#8211;K)</bold> *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.01, ***<italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g005.jpg"/></fig><p>Furthermore, by utilizing the immune therapy-related scores of various samples in the TCIA clinical database, we observed significant differences in the response among patients with high and low expression of the GLI1 gene. Specifically, there were significant differences in response for patients who were positive for CTLA-4 treatment and positive for PD-1 treatment (<italic toggle="yes">p</italic> = 1.7e-10), positive for CTLA-4 treatment and negative for PD-1 treatment (<italic toggle="yes">p</italic> = 5.2e-9), negative for CTLA-4 treatment and positive for PD-1 treatment (P = 4e-12), and negative for CTLA-4 treatment and negative for PD-1 treatment (<italic toggle="yes">p</italic> = 2.6e-10) (<xref rid="F5" ref-type="fig">Figures 5H&#8211;K</xref>).</p></sec><sec id="s3-6"><title>3.6 GLI1 expression associated functional pathways</title><p>We presents a differential expression analysis of genes associated with GLI1, highlighting significant changes in genes such as KERA, GXYLT2, and COL5A2 relative to GLI1. (<xref rid="F6" ref-type="fig">Figure 6A</xref>). GSEA was employed to investigate the functional pathways significantly associated with GLI1 expression. KEGG pathways, such as proteasome and mismatch repair, exhibited activation, while retinol metabolism showed a negative correlation with high GLI1 expression (<xref rid="F6" ref-type="fig">Figure 6B</xref>). Additionally, several immune-related GO terms were found to be associated with high GLI1 expression, including negative regulation of chromosome organization, DNA-dependent DNA replication, and retinol metabolism (<xref rid="F6" ref-type="fig">Figure 6C</xref>). These findings shed light on the potential mechanism underlying the involvement of GLI1 in immune status.</p><fig position="float" id="F6" orientation="portrait"><label>FIGURE 6</label><caption><p>Gene set difference analysis and enrichment analysis. Heat map of high and low differential expression of GLI1 and related genes <bold>(A)</bold>. GLI1 expression is significantly associated with KEGG pathways <bold>(B)</bold> and gene ontology terms <bold>(C)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g006.jpg"/></fig></sec><sec id="s3-7"><title>3.7 Prediction of drug sensitivity associated with expression of GLI1 in BRCA</title><p>Our study identified notable differences in drug sensitivity profiles among BRCA samples based on GLI1 expression levels.</p><p>Based on the GDSC module, we analyzed genomic data of the GLI1 gene and drug sensitivity data in BRCA tumors. We observed significant drug sensitivity of AGI-5198 in the GLI1 low-expression group (<italic toggle="yes">p</italic> = 0.018, <xref rid="F7" ref-type="fig">Figure 7A</xref>), whereas GSK1904529A exhibited significantly reduced sensitivity in the GLI1 low-expression group (<italic toggle="yes">p</italic> = 0.032, <xref rid="F7" ref-type="fig">Figure 7B</xref>). Similarly, Rapamycin showed higher drug sensitivity in the GLI1 low-expression group compared to the high-expression group (<italic toggle="yes">p</italic> = 0.015, <xref rid="F7" ref-type="fig">Figure 7C</xref>).</p><fig position="float" id="F7" orientation="portrait"><label>FIGURE 7</label><caption><p>Illustrates the expression of GLI1 in BRCA tumors under the influence of various drugs. <bold>(A)</bold> AGI-5198, <bold>(B)</bold> GSK1904529A, <bold>(C)</bold> Rapamycin, <bold>(D)</bold> Axitinib, <bold>(E)</bold> Bicalutamide, <bold>(F)</bold> Camptothecin, <bold>(G)</bold> Cisplatin, <bold>(H)</bold> Cytarabine, <bold>(I)</bold> Docetaxel, <bold>(J)</bold> Embelin, <bold>(K)</bold> Gemcitabine, <bold>(L)</bold> Imatinib, and <bold>(M)</bold> Lenalidomide.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-12-1478478-g007.jpg"/></fig><p>Using the TCGA module, we further explored the drug sensitivity spectrum of GLI1 in BRCA tumors. Axitinib demonstrated significant resistance in tumors with low GLI1 expression, whereas it exhibited better sensitivity in tumors with high GLI1 expression (<italic toggle="yes">p</italic> = 1.5e-07, <xref rid="F7" ref-type="fig">Figure 7D</xref>). In contrast, Bicalutamide showed higher drug sensitivity in samples with high GLI1 expression (<italic toggle="yes">p</italic> = 4.6e-08, <xref rid="F7" ref-type="fig">Figure 7E</xref>), potentially offering a therapeutic strategy for BRCA tumors. Additionally, Camptothecin (<italic toggle="yes">p</italic> = 1.3e-05, <xref rid="F7" ref-type="fig">Figure 7F</xref>) and Gemcitabine (<italic toggle="yes">p</italic> = 0.0081, <xref rid="F7" ref-type="fig">Figure 7H</xref>) displayed increased sensitivity in BRCA samples with high GLI1 expression. For Cisplatin, we observed a lower half-maximal inhibitory concentration in the high-expression group compared to the low-expression group (<italic toggle="yes">p</italic> = 0.00063, <xref rid="F7" ref-type="fig">Figure 7G</xref>), indicating a correlation between high GLI1 expression and increased drug sensitivity. Furthermore, Docetaxel exhibited significant drug sensitivity in tumors with high GLI1 expression (<italic toggle="yes">p</italic> = 0.0037, <xref rid="F7" ref-type="fig">Figure 7I</xref>), while Embelin showed enhanced sensitivity in samples with high GLI1 expression (<italic toggle="yes">p</italic> = 2.4e-15, <xref rid="F7" ref-type="fig">Figure 7J</xref>). Moreover, Gemcitabine (<italic toggle="yes">p</italic> = 0.0081, <xref rid="F7" ref-type="fig">Figure 7K</xref>) and Imatinib (<italic toggle="yes">p</italic> = 3.4e-05, <xref rid="F7" ref-type="fig">Figure 7L</xref>) demonstrated significantly enhanced drug sensitivity in tumors with high GLI1 expression. Lenalidomide showed higher sensitivity in the high-expression group compared to the low-expression group (<italic toggle="yes">p</italic> = 0.03, <xref rid="F7" ref-type="fig">Figure 7M</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>4 Discussion</title><p>Breast cancer is a leading cause of mortality among women globally, with its incidence progressively rising. However, the presence of heterogeneity poses challenges to early diagnosis and targeted therapy for breast cancer. Prognosis-associated molecular markers, including ER, PR, HER2, and Mib1/Ki-67, have gained considerable attention due to their demonstrated utility in clinical practice (<xref rid="B43" ref-type="bibr">Yan et al., 2020</xref>; <xref rid="B37" ref-type="bibr">Tarighati et al., 2023</xref>). Moreover, the emergence of innovative therapies like gene therapy and immunotherapy holds promise for effective treatment (<xref rid="B7" ref-type="bibr">Dastjerd et al., 2022</xref>; <xref rid="B44" ref-type="bibr">Yang et al., 2023</xref>). Therefore, it is imperative to identify additional prognostic biomarkers and explore new treatment strategies to optimize breast cancer management.</p><p>GLI1 has garnered significant attention for its paradoxical and multifunctional properties in various pathologies. It is recognized as a regulator of carcinogenesis and a potential therapeutic target in cancer (<xref rid="B35" ref-type="bibr">Sun et al., 2014</xref>; <xref rid="B23" ref-type="bibr">Li et al., 2016</xref>). However, the expression and specific roles of GLI1 in breast invasive carcinoma have been scarcely explored. Therefore, our study aims to comprehensively investigate the roles of GLI1 in breast invasive carcinoma.</p><p>Initial analysis across cancer types showed that GLI1 expression is downregulated in some (e.g., BLCA, BRCA) but upregulated in others (e.g., CHOL, KIRC), compared to normal tissues. This finding contradicted previous reports that showed elevated GLI1 expression in many cancers (<xref rid="B21" ref-type="bibr">Kubo et al., 2004</xref>; <xref rid="B41" ref-type="bibr">Wu and Dai, 2017</xref>; <xref rid="B33" ref-type="bibr">Sahu et al., 2022</xref>). The disparity in results may be attributed to sample differences and the paradoxical nature of GLI1. The differential expression of GLI1 in diverse cancers underscores its significance and potential as a therapeutic target.</p><p>Among the 33 cancer types studied, GLI1 exhibited lower expression in female tumors, including BRCA, CESC, and UCEC. In breast invasive carcinoma, GLI1 expression was significantly higher in normal tissue compared with tumor tissue. Immunohistochemical staining of clinical samples further confirmed the low expression of GLI1 in tumor tissue. Notably, patients with lower GLI1 expression during the first 8&#160;years of illness experienced worse survival outcomes. Further correlation analysis of clinical data revealed differences in GLI1 expression between patients older and younger than 65&#160;years old, as well as among different pathological stages and T stages. These differences held certain guiding significance. Consequently, this indirectly explained why BRCA patients with low GLI1 expression had a poorer survival outcome. Effective prognostic biomarkers play a crucial role in clinical management and treatment decision-making, providing essential information regarding tumor progression and clinical outcomes. Our analyses confirm that GLI1 serves as a prognostic biomarker in breast invasive carcinoma, correlating with pathological stages and survival outcomes in this disease.</p><p>Multiple immunotherapies, such as CTLA-4-, PD-1-, and PD-L1-specific immune checkpoint antagonists, have been developed in breast cancer to effectively enhance patient survival. However, currently available immunotherapies for breast cancer have been associated with drug resistance and adverse events (thyroid dysfunction and adrenocortical hypofunction, etc.). The effectiveness of immunotherapy primarily relies on the infiltrating immune cells within the TMIE, which play a crucial role in modulating tumor progression through dynamic and extensive crosstalk with tumor cells (<xref rid="B48" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B45" ref-type="bibr">Yang et al., 2022</xref>). Various molecules have been shown to participate in this intercellular crosstalk (<xref rid="B16" ref-type="bibr">Inaguma et al., 2013</xref>; <xref rid="B47" ref-type="bibr">Zhang et al., 2017</xref>).</p><p>Our study explores the expression pattern of GLI1 in BRCA and lays the foundation for investigating its potential immunoregulatory role, with a focus on correlating GLI1 expression with immune cell infiltration and checkpoint molecules. Additionally, functional hypotheses are proposed based on the observed correlations to further investigate the underlying mechanisms of GLI1 in BRCA immunity.</p><p>High expression of GLI1 positively correlated with the abundance of infiltrating immune cells, such as DCs and CD4<sup>+</sup> T cells, suggesting that GLI1 may partially regulate the recruitment of immune cells in the TMIE of breast invasive carcinoma. Furthermore, we observed a strong correlation between high GLI1 expression and multiple immune checkpoints, immune status-related genes, and chemokine-related genes. Correlation analysis of immunotherapy demonstrated significant differences in efficacy between groups with high or low expression of GLI1 under different immunotherapy regimens, indicating that GLI1 may influence immunotherapy through potential mechanisms.</p><p>Based on the observed correlations between GLI1 expression and immune cell infiltration, as well as its co-expression with immune-related genes, we hypothesize that GLI1 plays a pivotal role in modulating the immune microenvironment within BRCA. Specifically, we propose that GLI1 may regulate immune cell infiltration and activation by influencing the expression of chemokines, cytokines, and other immune modulators. Moreover, the association of GLI1 with immune checkpoint molecules, such as CTLA-4 and PD-1, suggests that GLI1 may influence the efficacy of immunotherapy by modulating immune cell exhaustion and activation. To validate these hypotheses, further functional studies, including <italic toggle="yes">in vitro</italic> cell culture experiments and <italic toggle="yes">in vivo</italic> animal models, are warranted to examine the direct effects of GLI1 on immune cell function and BRCA tumor progression. Such experiments would provide crucial insights into the molecular mechanisms underlying the immunoregulatory role of GLI1 in BRCA and potentially guide the development of novel immunotherapeutic strategies targeting GLI1.</p><p>In the context of our study, the observed activation of proteasome, inhibition of mismatch repair (MMR), and the negative correlation with retinol metabolism pathways, as well as the differential GO terms, offer important insights into the complex mechanisms underlying GLI1-mediated breast cancer progression. Specifically, the activation of the proteasome pathway highlights GLI1&#8217;s potential role in regulating protein homeostasis, which is crucial for maintaining cellular functions and processes that drive cancer progression. By modulating the degradation of GLI1 and other proteins, the proteasome may influence GLI1&#8217;s oncogenic activities, as suggested by previous studies (<xref rid="B26" ref-type="bibr">Morrison et al., 2020</xref>). This finding underscores the need for further investigation into the specific mechanisms linking proteasome activity and GLI1 regulation in breast cancer. Moreover, the inhibition of MMR pathways observed in our study aligns with previous reports indicating that GLI1 can interfere with MMR, potentially leading to genomic instability and accelerated cancer progression (<xref rid="B16" ref-type="bibr">Inaguma et al., 2013</xref>). This finding further emphasizes the oncogenic potential of GLI1 in breast cancer and highlights the importance of understanding its role in maintaining genomic stability. Interestingly, the negative correlation between retinol metabolism and GLI1 high expression suggests a potential regulatory loop between these two pathways. Retinoic acid, a metabolite of retinol, has been shown to regulate GLI1 expression and Hedgehog signaling (<xref rid="B13" ref-type="bibr">Hong et al., 2024</xref>), which is frequently dysregulated in breast cancer (<xref rid="B3" ref-type="bibr">An et al., 2021</xref>). Our results indicate that this regulatory loop may be disrupted in GLI1-high breast cancer cells, leading to alterations in retinol metabolism and contributing to cancer progression. This finding has important implications for breast cancer therapy, as targeting retinol metabolism or Hedgehog signaling may represent novel therapeutic strategies for GLI1-driven breast cancers.</p><p>Due to the preliminary nature of this study, limitations exist in understanding how GLI1 is adapted and regulated by immunotherapy. Further in-depth mechanistic investigations are necessary, such as employing transwell invasion assays and wound healing assays to explore the impact of GLI1 on cellular behavior within the immune microenvironment of invasive breast cancer (<xref rid="B13" ref-type="bibr">Hong et al., 2024</xref>; <xref rid="B39" ref-type="bibr">Wang et al., 2023</xref>). Additionally, targeting GLI1 as a key gene may facilitate the screening of effective therapeutic agents (<xref rid="B3" ref-type="bibr">An et al., 2021</xref>), contributing to the advancement of personalized treatment approaches for breast cancer and promoting relevant clinical trials for combination immunotherapy.</p></sec><sec sec-type="conclusion" id="s5"><title>5 Conclusion</title><p>In summary, this study extensively investigates the expression of GLI1 in BRCA and its immunoregulatory role. The findings provide evidence of low GLI1 expression in BRCA, which may serve as a prognostic indicator for patient survival. We have established a close association between GLI1 and the immune status of BRCA, indicating its potential as a biomarker or specific target for immunotherapy in BRCA. Further research is warranted to elucidate the role of GLI1 in BRCA.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>Publicly available datasets were used in this study. The TCGA gene expressions along with the clinical datasets were downloaded from the TCGA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tcga.xenahubs.net" ext-link-type="uri">https://tcga.xenahubs.net</ext-link>), GTEx database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://commonfund.nih.gov/GTEx/" ext-link-type="uri">http://commonfund.nih.gov/GTEx/</ext-link>) and TCIA database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tcia.at/" ext-link-type="uri">https://tcia.at/</ext-link>).</p></sec><sec id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Committee of Xi&#8217;an NO.3 Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec id="s8"><title>Author contributions</title><p>TQ: Conceptualization, Data curation, Methodology, Software, Visualization, Writing&#8211;original draft. YH: Data curation, Software, Visualization, Writing&#8211;original draft. JW: Software, Validation, Writing&#8211;original draft. BZ: Visualization, Writing&#8211;original draft. JX: Methodology, Writing&#8211;original draft. JL: Writing&#8211;review and editing. YC: Writing&#8211;review and editing. HW: Funding acquisition, Methodology, Writing&#8211;review and editing. YL: Funding acquisition, Supervision, Writing&#8211;review and editing. FJ: Funding acquisition, Writing&#8211;review and editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2024.1478478/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fcell.2024.1478478/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.docx" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>S.</given-names></name><name name-style="western"><surname>Othus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Chugh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schuetze</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609)</article-title>. <source>Clin. Cancer Res.</source><volume>28</volume> (<issue>2</issue>), <fpage>271</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-21-2182</pub-id><pub-id pub-id-type="pmid">34716198</pub-id><pub-id pub-id-type="pmcid">PMC8776596</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akiyoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuneyoshi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation</article-title>. <source>Gut</source><volume>55</volume> (<issue>7</issue>), <fpage>991</fpage>&#8211;<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1136/gut.2005.080333</pub-id><pub-id pub-id-type="pmid">16299030</pub-id><pub-id pub-id-type="pmcid">PMC1856354</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Exosomes from adipose-derived stem cells and application to skin wound healing</article-title>. <source>Cell Prolif.</source><volume>54</volume> (<issue>3</issue>), <fpage>e12993</fpage>. <pub-id pub-id-type="doi">10.1111/cpr.12993</pub-id><pub-id pub-id-type="pmid">33458899</pub-id><pub-id pub-id-type="pmcid">PMC7941238</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zenklusen</surname><given-names>J. C.</given-names></name></person-group> (<year>2018</year>). <article-title>SnapShot: TCGA-analyzed tumors</article-title>. <source>Cell</source><volume>173</volume> (<issue>2</issue>), <fpage>530</fpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.059</pub-id><pub-id pub-id-type="pmid">29625059</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perica</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klebanoff</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name></person-group> (<year>2022</year>). <article-title>Clinical implications of T cell exhaustion for cancer immunotherapy</article-title>. <source>Nat. Rev. Clin. Oncol.</source><volume>19</volume> (<issue>12</issue>), <fpage>775</fpage>&#8211;<lpage>790</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-022-00689-z</pub-id><pub-id pub-id-type="pmid">36216928</pub-id><pub-id pub-id-type="pmcid">PMC10984554</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahmane</surname><given-names>N.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gitton</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Beyna</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis</article-title>. <source>Development</source><volume>128</volume> (<issue>24</issue>), <fpage>5201</fpage>&#8211;<lpage>5212</lpage>. <pub-id pub-id-type="doi">10.1242/dev.128.24.5201</pub-id><pub-id pub-id-type="pmid">11748155</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dastjerd</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Valibeik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rahimi Monfared</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goodarzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moradi Sarabi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hajabdollahi</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Gene therapy: a promising approach for breast cancer treatment</article-title>. <source>Cell Biochem. Funct.</source><volume>40</volume> (<issue>1</issue>), <fpage>28</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.3676</pub-id><pub-id pub-id-type="pmid">34904722</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeSantis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bandi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Breast cancer statistics, 2011</article-title>. <source>CA Cancer J. Clin.</source><volume>61</volume> (<issue>6</issue>), <fpage>409</fpage>&#8211;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.3322/caac.20134</pub-id><pub-id pub-id-type="pmid">21969133</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Echelard</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>St-Jacques</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mohler</surname><given-names>J.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity</article-title>. <source>Cell</source><volume>75</volume> (<issue>7</issue>), <fpage>1417</fpage>&#8211;<lpage>1430</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(93)90627-3</pub-id><pub-id pub-id-type="pmid">7916661</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Zapico</surname><given-names>M. E.</given-names></name></person-group> (<year>2013</year>). <article-title>GLI1 finds a new role in cancer stem cell biology</article-title>. <source>EMBO Mol. Med.</source><volume>5</volume> (<issue>4</issue>), <fpage>483</fpage>&#8211;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201302505</pub-id><pub-id pub-id-type="pmid">23505092</pub-id><pub-id pub-id-type="pmcid">PMC3628101</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Str&#246;mblad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A feedback regulation between Kindlin-2 and GLI1 in prostate cancer cells</article-title>. <source>FEBS Lett.</source><volume>587</volume> (<issue>6</issue>), <fpage>631</fpage>&#8211;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2012.12.028</pub-id><pub-id pub-id-type="pmid">23337877</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling</article-title>. <source>Mol. Cancer</source><volume>20</volume> (<issue>1</issue>), <fpage>132</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-021-01435-2</pub-id><pub-id pub-id-type="pmid">34649567</pub-id><pub-id pub-id-type="pmcid">PMC8515748</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group> (<year>2024</year>). <article-title>Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value</article-title>. <source>J. Ovarian Res.</source><volume>17</volume> (<issue>1</issue>), <fpage>64</fpage>. <pub-id pub-id-type="doi">10.1186/s13048-024-01386-4</pub-id><pub-id pub-id-type="pmid">38493179</pub-id><pub-id pub-id-type="pmcid">PMC10943877</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Angers</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Gli proteins in development and disease</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source><volume>27</volume>, <fpage>513</fpage>&#8211;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154048</pub-id><pub-id pub-id-type="pmid">21801010</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichimiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakihama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer</article-title>. <source>Oncol. Rep.</source><volume>45</volume> (<issue>3</issue>), <fpage>997</fpage>&#8211;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.3892/or.2021.7947</pub-id><pub-id pub-id-type="pmid">33650666</pub-id><pub-id pub-id-type="pmcid">PMC7860001</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inaguma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riku</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1</article-title>. <source>Cancer Res.</source><volume>73</volume> (<issue>24</issue>), <fpage>7313</fpage>&#8211;<lpage>7323</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-13-2008</pub-id><pub-id pub-id-type="pmid">24165159</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandala</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells <italic toggle="yes">in vitro</italic> and blocks tumor formation ability <italic toggle="yes">in vivo</italic>
</article-title>. <source>J. Biol. Chem.</source><volume>287</volume> (<issue>34</issue>), <fpage>28745</fpage>&#8211;<lpage>28754</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.351379</pub-id><pub-id pub-id-type="pmid">22773833</pub-id><pub-id pub-id-type="pmcid">PMC3436512</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinzler</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Bigner</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Bigner</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Trent</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Law</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>1987</year>). <article-title>Identification of an amplified, highly expressed gene in a human glioma</article-title>. <source>Science</source><volume>236</volume> (<issue>4797</issue>), <fpage>70</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1126/science.3563490</pub-id><pub-id pub-id-type="pmid">3563490</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinzler</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Ruppert</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Bigner</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group> (<year>1988</year>). <article-title>The GLI gene is a member of the Kruppel family of zinc finger proteins</article-title>. <source>Nature</source><volume>332</volume> (<issue>6162</issue>), <fpage>371</fpage>&#8211;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1038/332371a0</pub-id><pub-id pub-id-type="pmid">2832761</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinzler</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group> (<year>1990</year>). <article-title>The GLI gene encodes a nuclear protein which binds specific sequences in the human genome</article-title>. <source>Mol. Cell Biol.</source><volume>10</volume> (<issue>2</issue>), <fpage>634</fpage>&#8211;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.10.2.634</pub-id><pub-id pub-id-type="pmid">2105456</pub-id><pub-id pub-id-type="pmcid">PMC360861</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer</article-title>. <source>Cancer Res.</source><volume>64</volume> (<issue>17</issue>), <fpage>6071</fpage>&#8211;<lpage>6074</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-04-0416</pub-id><pub-id pub-id-type="pmid">15342389</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title>. <source>Nucleic Acids Res.</source><volume>48</volume> (<issue>W1</issue>), <fpage>W509-W514</fpage>&#8211;<lpage>w514</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa407</pub-id><pub-id pub-id-type="pmid">32442275</pub-id><pub-id pub-id-type="pmcid">PMC7319575</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>WW45, a Gli1 binding protein, negatively regulated Hedgehog signaling in lung cancer</article-title>. <source>Oncotarget</source><volume>7</volume> (<issue>42</issue>), <fpage>68966</fpage>&#8211;<lpage>68975</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.12155</pub-id><pub-id pub-id-type="pmid">27661123</pub-id><pub-id pub-id-type="pmcid">PMC5356604</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loibl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poortmans</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Denkert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Curigliano</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Breast cancer</article-title>. <source>Lancet</source><volume>397</volume> (<issue>10286</issue>), <fpage>1750</fpage>&#8211;<lpage>1769</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)32381-3</pub-id><pub-id pub-id-type="pmid">33812473</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonsdale</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shad</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>The genotype-tissue expression (GTEx) project</article-title>. <source>Nat. Genet.</source><volume>45</volume> (<issue>6</issue>), <fpage>580</fpage>&#8211;<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2653</pub-id><pub-id pub-id-type="pmid">23715323</pub-id><pub-id pub-id-type="pmcid">PMC4010069</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>V. E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Retinoic acid is required for oligodendrocyte precursor cell production and differentiation in the postnatal mouse corpus callosum</article-title>. <source>eNeuro</source><volume>7</volume> (<issue>1</issue>), <fpage>ENEURO.0270</fpage>&#8211;<lpage>19.2019</lpage>. <pub-id pub-id-type="doi">10.1523/eneuro.0270-19.2019</pub-id><pub-id pub-id-type="pmid">31879367</pub-id><pub-id pub-id-type="pmcid">PMC6977210</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shatsky</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pusztai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial</article-title>. <source>JAMA Oncol.</source><volume>6</volume> (<issue>5</issue>), <fpage>676</fpage>&#8211;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2019.6650</pub-id><pub-id pub-id-type="pmid">32053137</pub-id><pub-id pub-id-type="pmcid">PMC7058271</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olive</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Jacobetz</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Gopinathan</surname><given-names>A.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honess</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer</article-title>. <source>Science</source><volume>324</volume> (<issue>5933</issue>), <fpage>1457</fpage>&#8211;<lpage>1461</lpage>. <pub-id pub-id-type="doi">10.1126/science.1171362</pub-id><pub-id pub-id-type="pmid">19460966</pub-id><pub-id pub-id-type="pmcid">PMC2998180</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perou</surname><given-names>C. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Deconstructing the molecular portraits of breast cancer</article-title>. <source>Mol. Oncol.</source><volume>5</volume> (<issue>1</issue>), <fpage>5</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.molonc.2010.11.003</pub-id><pub-id pub-id-type="pmid">21147047</pub-id><pub-id pub-id-type="pmcid">PMC5528267</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Expression of Shh, Gli1, and Cyr61 in gastric cancer predicts overall survival of patients: a retrospective study</article-title>. <source>Cancer control.</source><volume>29</volume>, <fpage>10732748221134398</fpage>. <pub-id pub-id-type="doi">10.1177/10732748221134398</pub-id><pub-id pub-id-type="pmid">36346167</pub-id><pub-id pub-id-type="pmcid">PMC9647287</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riggio</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Varley</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Welm</surname><given-names>A. L.</given-names></name></person-group> (<year>2021</year>). <article-title>The lingering mysteries of metastatic recurrence in breast cancer</article-title>. <source>Br. J. Cancer</source><volume>124</volume> (<issue>1</issue>), <fpage>13</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/s41416-020-01161-4</pub-id><pub-id pub-id-type="pmid">33239679</pub-id><pub-id pub-id-type="pmcid">PMC7782773</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roelink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Augsburger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heemskerk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korzh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Norlin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruiz i Altaba</surname><given-names>A.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord</article-title>. <source>Cell</source><volume>76</volume> (<issue>4</issue>), <fpage>761</fpage>&#8211;<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(94)90514-2</pub-id><pub-id pub-id-type="pmid">8124714</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kraehenbuehl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Byers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tembo</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>
<italic toggle="yes">In vivo</italic> tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response</article-title>. <source>Nat. Commun.</source><volume>13</volume> (<issue>1</issue>), <fpage>5312</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-32738-7</pub-id><pub-id pub-id-type="pmid">36085288</pub-id><pub-id pub-id-type="pmcid">PMC9463451</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;rlie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perou</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Geisler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnsen</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>98</volume> (<issue>19</issue>), <fpage>10869</fpage>&#8211;<lpage>10874</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><pub-id pub-id-type="pmid">11553815</pub-id><pub-id pub-id-type="pmcid">PMC58566</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells</article-title>. <source>Cell Death Dis.</source><volume>5</volume> (<issue>1</issue>), <fpage>e979</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.497</pub-id><pub-id pub-id-type="pmid">24384722</pub-id><pub-id pub-id-type="pmcid">PMC4040663</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title>. <source>Nucleic Acids Res.</source><volume>45</volume> (<issue>W1</issue>), <fpage>W98-W102</fpage>&#8211;<lpage>w102</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmid">28407145</pub-id><pub-id pub-id-type="pmcid">PMC5570223</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarighati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Keivan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahani</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>A review of prognostic and predictive biomarkers in breast cancer</article-title>. <source>Clin. Exp. Med.</source><volume>23</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-021-00781-1</pub-id><pub-id pub-id-type="pmid">35031885</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-&#953;/GLI1 pathway</article-title>. <source>Cell Death Dis.</source><volume>9</volume> (<issue>11</issue>), <fpage>1115</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-018-1145-1</pub-id><pub-id pub-id-type="pmid">30389910</pub-id><pub-id pub-id-type="pmcid">PMC6214900</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Identification of A Novel gene signature combining ferroptosis- and immunity-related genes for prognostic prediction, immunotherapy and potential therapeutic targets in gastric cancer</article-title>. <source>J. Cancer</source><volume>14</volume> (<issue>18</issue>), <fpage>3457</fpage>&#8211;<lpage>3476</lpage>. <pub-id pub-id-type="doi">10.7150/jca.87223</pub-id><pub-id pub-id-type="pmid">38021154</pub-id><pub-id pub-id-type="pmcid">PMC10647194</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Remodeling chondroitin-6-sulfate-mediated immune exclusion enhances anti-PD-1 response in colorectal cancer with microsatellite stability</article-title>. <source>Cancer Immunol. Res.</source><volume>10</volume> (<issue>2</issue>), <fpage>182</fpage>&#8211;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.Cir-21-0124</pub-id><pub-id pub-id-type="pmid">34933913</pub-id><pub-id pub-id-type="pmcid">PMC9414301</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Tumor microenvironment and therapeutic response</article-title>. <source>Cancer Lett.</source><volume>387</volume>, <fpage>61</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.043</pub-id><pub-id pub-id-type="pmid">26845449</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Sonic hedgehog-Gli1 signaling pathway regulates the epithelial mesenchymal transition (EMT) by mediating a new target gene, S100A4, in pancreatic cancer cells</article-title>. <source>PLoS One</source><volume>9</volume> (<issue>7</issue>), <fpage>e96441</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0096441</pub-id><pub-id pub-id-type="pmid">25072505</pub-id><pub-id pub-id-type="pmcid">PMC4114558</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Diagnosis and treatment of breast cancer in the precision medicine era</article-title>. <source>Methods Mol. Biol.</source><volume>2204</volume>, <fpage>53</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-0904-0_5</pub-id><pub-id pub-id-type="pmid">32710314</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D. Q.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy</article-title>. <source>Cell Metab.</source><volume>35</volume> (<issue>1</issue>), <fpage>84</fpage>&#8211;<lpage>100.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2022.09.021</pub-id><pub-id pub-id-type="pmid">36257316</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis</article-title>. <source>Nat. Commun.</source><volume>13</volume> (<issue>1</issue>), <fpage>5782</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-33349-y</pub-id><pub-id pub-id-type="pmid">36184646</pub-id><pub-id pub-id-type="pmcid">PMC9527239</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shahmoradgoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vegesna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Torres-Garcia</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title>. <source>Nat. Commun.</source><volume>4</volume>, <fpage>2612</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms3612</pub-id><pub-id pub-id-type="pmid">24113773</pub-id><pub-id pub-id-type="pmcid">PMC3826632</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Ka-Wai Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G. J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through &#946;-TrCP-mediated proteasome degradation</article-title>. <source>Oncotarget</source><volume>8</volume> (<issue>30</issue>), <fpage>49869</fpage>&#8211;<lpage>49881</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.17769</pub-id><pub-id pub-id-type="pmid">28562331</pub-id><pub-id pub-id-type="pmcid">PMC5564814</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Extracellular vesicle long non-coding RNA-mediated crosstalk in the tumor microenvironment: tiny molecules, huge roles</article-title>. <source>Cancer Sci.</source><volume>111</volume> (<issue>8</issue>), <fpage>2726</fpage>&#8211;<lpage>2735</lpage>. <pub-id pub-id-type="doi">10.1111/cas.14494</pub-id><pub-id pub-id-type="pmid">32437078</pub-id><pub-id pub-id-type="pmcid">PMC7419043</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications</article-title>. <source>Cell Mol. Immunol.</source><volume>17</volume> (<issue>8</issue>), <fpage>807</fpage>&#8211;<lpage>821</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0488-6</pub-id><pub-id pub-id-type="pmid">32612154</pub-id><pub-id pub-id-type="pmcid">PMC7395159</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>H. W.</given-names></name></person-group> (<year>2010</year>). <article-title>The human glioma-associated Oncogene homolog 1 (GLI1) family of transcription factors in gene regulation and diseases</article-title>. <source>Curr. Genomics</source><volume>11</volume> (<issue>4</issue>), <fpage>238</fpage>&#8211;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.2174/138920210791233108</pub-id><pub-id pub-id-type="pmid">21119888</pub-id><pub-id pub-id-type="pmcid">PMC2930663</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>